Bio-Technology General Corp. has entered into an exclusive agreement with DePuy Orthopaedics Inc. (DePuy), for BioHy, BTG’s proprietary high molecular weight sodium hyaluronate product, for the treatment of pain associated with osteoarthritis of the knee. The agreement grants DePuy exclusive marketing rights to BioHy in all countries worldwide except Japan and Israel. Clinical efforts, where Read more about Bio-Technology General Signs Deal For BioTechnology[…]